Mme Docteur Francoise DURAND

Thèses universitaires

• Autisme et psychoses infantiles : limites du concept : application au suivi clinique des enfants admis dans le service de pedo-psychiatrie du chru de clermont-ferrand

  1988
  Médecine🎓 Clermont-Ferrand 1

  Direction : André-Julien Coudert

Source : catalogue national des thèses theses.fr (ABES). Ne couvre que les doctorats / HDR — les thèses d'exercice (DES) sont archivées dans les SCD universitaires.

Bibliographie

• MRI management of NMOSD and MOGAD: Proposals from the French Expert Group NOMADMUS

  2025

  ArticleJournal de Neuroradiologie / Journal of Neuroradiology

• Natural history of adult-onset metachromatic leukodystrophy

  2025

  ArticleJournal of Neurology

• Evaluation of a deep learning segmentation tool to help detect spinal cord lesions from combined T2 and STIR acquisitions in people with multiple sclerosis

  2025

  ArticleEuropean Radiology

• Limited added value of systematic spinal cord MRI vs brain MRI alone to classify patients with MS as active or inactive during follow-up

  2025

  ArticleJournal of Neurology

• Explainable Monotonic Networks and Constrained Learning for Interpretable Classification and Weakly Supervised Anomaly Detection

  2025

  ArticlePattern Recognition

• Enhanced brain tissue contrast in MRI by optimal control in 3D Double Inversion Recovery sequence with a view to improving cortical lesions detection in multiple sclerosis

  2024

  CongrèsESMRMB 2024, 40th Annual Scientific Meeting of the European Society for Magnetic Resonance in Medicine and Biology.

• Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations

  2024

  ArticleRevue Neurologique

• Choroid plexus enlargement correlates with periventricular pathology but not with disease activity in radiologically isolated syndrome

  2024

  ArticleMultiple Sclerosis Journal

Source : HAL — archive ouverte CCSD/CNRS (couvre articles, chapitres EMC, communications congrès, thèses).

Localisation

Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.

Lieu de consultation

• CABINET DU DR FRANCOISE DURAND

  MAISON MEDICALE, 15260 Neuvéglise-sur-Truyère

  Libéral
  © OpenStreetMap

  📷 Street View ↗🗺️ Maps ↗OSM ↗

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).

Top publications · les plus citées

• 1

  Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis

  Rheumatology international · 2018

  📚 84 citations🎯 RCR 5.30Top 7% NIH🔓 Open Access📄 PDF gratuit ↗
• 2

  Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

  Journal of clinical medicine · 2019

  📚 66 citations🎯 RCR 3.45Top 13% NIH🔓 Open Access📄 PDF gratuit ↗

  Lire l'abstract Crossref ↓

  The purpose of the study was to assess the proportion of patients who achieve pain relief thresholds, the time needed to reach the thresholds, and the relationship between pain and inflammation among patients with rheumatoid arthritis (RA) and an inadequate response to methotrexate in RA-BEAM (NCT0170358). A randomized, double-blind trial was conducted, comparing baricitinib (N = 487), adalimumab (N = 330), and placebo (N = 488) plus methotrexate. Pain was evaluated by patient’s assessment on a 0–100 mm visual analog scale (VAS). The following were assessed through a 24-week placebo-controlled period: the proportion of patients who achieved ≥30%, ≥50%, and ≥70% pain relief, the time to achieve these pain relief thresholds, remaining pain (VAS ≤ 10 mm, ≤20 mm, or ≤40 mm), and the relationship between inflammation markers and pain relief. Baricitinib-treated patients were more likely (p < 0.05) to achieve ≥30%, ≥50%, and ≥70% pain relief than placebo- and adalimumab-treated patients, as early as Week 1 vs. placebo and at Week 4 vs. adalimumab. A greater proportion of baricitinib-treated patients achieved ≤20 mm or ≤40 mm remaining pain vs. placebo- and adalimumab-treated patients. Baricitinib-treated patients tended to demonstrate consistent pain relief independent of levels of inflammation control. In RA patients with an inadequate response to methotrexate, baricitinib provided greater and more rapid pain relief than adalimumab and placebo. Analyses suggest the relationship between inflammation and pain may be different for baricitinib and adalimumab treatments.

• 3

  Continuous cefazolin infusion to treat bone and joint infections: clinical efficacy, feasibility, safety, and serum and bone concentrations

  Antimicrobial agents and chemotherapy · 2009

  📚 51 citations🎯 RCR 2.04

  Lire l'abstract Crossref ↓

  ABSTRACT Cefazolin has been used for many years to treat bone and joint infections. Because of its time-dependent antimicrobial activity, continuous infusion would potentially be beneficial. We report on the feasibility, safety, and efficacy of prolonged continuous intravenous cefazolin therapy in a cohort of 100 patients, their serum cefazolin levels, and the concomitant bone cefazolin concentrations in 8 of them. This retrospective cohort study included all the patients treated for bone or joint infection with a continuous cefazolin infusion administered over a 12-h period twice daily for ≥2 weeks. Drug monitoring was performed at least twice for all the patients. Serum and bone cefazolin concentrations were determined by standardized disk diffusion microbiological assays. The absence of clinical, biological, and radiological signs of infection after 2 years of follow-up and the same criteria after 1 year of follow-up defined cures and probable cures, respectively. The median treatment duration was 42 days, and the median daily cefazolin dose was 6 g. Half of the patients received parenteral antibiotic therapy on an outpatient basis. Two moderate-grade adverse events were observed. The median serum cefazolin concentrations were 63 μg/ml (range, 13 to 203 μg/ml) and 57 μg/ml (range, 29 to 128 μg/ml) on days 2 to 10 and days 11 to 21, respectively. The median bone cefazolin concentration reached 13.5 μg/g (range, 3.5 to 29 μg/g). The median bone concentration/serum concentration ratio was 0.25 (range, 0.06 to 0.41). Among 88 patients with a median follow-up of 25 months (range, 12 to 53 months), 52 were considered cured and 29 were considered probably cured. Thus, the treatment of bone and joint infections with a prolonged continuous intravenous cefazolin infusion was feasible, effective, well-tolerated, safe, and convenient, making it a strong candidate for home therapy.

Publications scientifiques (12) — classées par pathologie

Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).

Partager cette fiche